For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer,
Surveyed Oncologists Indicate that Improved Symptom Control and Quality of
Life is one of the Greatest Unmet Needs
Surveyed U.S. Payers Are Most Receptive to Therapies Offering a Significant
Median Overall Survival Benefit over Currently Available Therapies, According
to a New Report from Decision Resources
BURLINGTON, Mass., June 5, 2013
BURLINGTON, Mass., June 5, 2013 /PRNewswire/ --Decision Resources, one of the
world's leading research and advisory firms for pharmaceutical and healthcare
issues, finds that symptom control and quality of life is one of the factors
the most influences surveyed U.S. and European oncologists' treatment
decisions for second- and subsequent-line metastatic castrate-resistant
prostate cancer (mCRPC), and that improved symptom control and quality of life
is one of the greatest unmet needs in this indication. Interviewed thought
leaders expressed optimism that cabozantinib (Exelixis's Cometriq) and
radium-223 (Algeta/Bayer HealthCare's Xofigo) will have an advantage over
sales-leading abiraterone (Johnson & Johnson/Janssen Biotech/Janssen-Cilag's
Zytiga) on this attribute and will help to partially fulfill the large unmet
(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )
The DecisionBase 2013 report entitled Prostate Cancer (Second- and
Subsequent-Line Metastatic Castrate-Resistant): What Advantages Do Surveyed
Oncologists and Payers Believe Emerging Therapies Have to Offer in Order to
Gain Traction in This Crowded and Competitive Market finds that surveyed U.S.
managed care organization pharmacy directors are most willing to grant
favorable formulary status to new second- and subsequent-line mCRPC therapies
offering increased median overall survival (MOS) over currently available
treatment options. Nevertheless, nearly half of the surveyed payers indicated
that they would not reimburse a new therapy priced the same as enzalutamide
(Medivation/Astellas Pharma's Xtandi) or higher that offered a three-month
improvement in median overall survival over enzalutamide, most commonly
stating insufficient clinical benefit to grant reimbursement.
The report also finds that surveyed U.S. oncologists would prescribe the
emerging hormonal agent orteronel (Takeda/Millennium) to 25 percent of their
second- and subsequent-line mCRPC patients - however, Decision Resources
forecasts that orteronel will earn a more conservative patient share owing
primarily to its late launch compared with its main competitors - abiraterone
and enzalutamide -in the United States.
"Early-stage clinical data for orteronel are encouraging," said Decision
Resources Senior Business Insight Analyst Dr. Karen Pomeranz. "Thought leaders
are enthusiastic about hormonal therapies, in particular CYP17 inhibitors and
state that they offer high efficacy and a more manageable safety and
tolerability profile compared with that associated with standard chemotherapy.
However, by the time orteronel will reach the market, the current hormonal
therapies, abiraterone and enzalutamide, will have become well entrenched in
the treatment algorithm for second- and subsequent-line mCRPC."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
SOURCE Decision Resources
Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.